摘要
目的:比较胸腔内注射尿激酶或糖皮质激素治疗结核性胸膜炎的疗效性和安全性。方法:计算机检索Medline、Embase、Cochrane-library、Web of science、中国生物医学文献数据库、中文科技期刊数据库、中国知网、万方医学网数据库,并辅以手工检索从建库起至2014年11月关于胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效比较的随机对照研究文献,采用Rev Man 5.2.3软件行数据分析。结果:纳入5项研究,Meta分析显示,尿激酶组和激素组的胸水完全吸收时间(RR=0.48,P=0.22)、胸膜增厚发生率(RR=0.67,P=0.06)及不良反应(RR=1.17,P=0.70)差异无统计学意义;胸膜厚度有明显异质性(I2=91%),不予Meta合并。结论:胸腔内注入尿激酶或激素治疗结核性胸膜炎疗效和安全性比较无显著差异。
Objective： To evaluate the efficacy and safety of intrapleural urokinase or glucocorticoid in treatment of tuberculous pleural effusion. Methods： All randomized controlled trials,which studied comparison of effects between intrapleural urokinase or glusocorticoid for tuberculous pleural effusion,were searched from Medline,Embase,Cochrane-library,Web of science,Chinese Biomedical Literature Database,Chinese National Knowledge Infrastructure,Chinese Scientific Journal Database,Wanfang Med Online Database up to November 2014. All were searched by manual and computer retrieval. Rev Man 5. 2. 3 was used for data analysis. Results： Five literatures were included in this study. No statistical difference was found between urokinase group and glucocorticoid group on hydrothorax absorption days（ RR = 0. 48,P = 0. 22）,the incidence of pleural thickening（ RR = 0. 67,P = 0. 06）and adverse reaction（ RR = 1. 17,P = 0. 70）. But due to significant heterogeneity,the description rather than Metaanalysis was managed on index of thickness of pleura（ I2= 91%）. Conclusion： There is no significant difference between intrapleural urokinase and glucocorticoid on effects and safety in the treatment of tuberculous pleural effusion.
出处
《东南大学学报（医学版）》
CAS
北大核心
2015年第3期369-372,共4页
Journal of Southeast University(Medical Science Edition)
基金
国家自然科学基金资助项目(810710101)
四川省教育厅基金资助项目(12ZA060)
